"At Minnesota Oncology, we are dedicated to providing compassionate care for various types of cancer and blood disorders in 12 convenient Twin Cities metro locations as well as several satellite locations. Our mission is to combine the strength of hope with the power of science, one patient at a time."

During the past decade, Minnesota Oncology Hematology , P.A. conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 41 clinical trials were completed, i.e. on average, 107.9% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 19 clinical trials were completed. i.e. 146.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minnesota Oncology Hematology , P.A." #1 sponsor was "US Oncology Research" with 13 trials, followed by "Eli Lilly and Company" with 7 trials sponsored, "Seagen Inc." with 7 trials sponsored, "Bristol-Myers Squibb" with 6 trials sponsored and "Celgene" with 6 trials sponsored. Other sponsors include 46 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minnesota Oncology Hematology , P.A." #1 collaborator was "Bristol-Myers Squibb" with 5 trials as a collaborator, "Sanofi" with 4 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator and "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Minnesota Oncology Hematology , P.A." are "Breast Cancer" (11 trials), "Metastatic Breast Cancer" (11 trials), "Non-small Cell Lung Cancer" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials) and "Ovarian Cancer" (4 trials). Many other conditions were trialed in "Minnesota Oncology Hematology , P.A." in a lesser frequency.

Most popular intervention types in "Minnesota Oncology Hematology , P.A." are "Drug" (75 trials), "Biological" (14 trials), "Other" (8 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Nivolumab" (7 trials), "Carboplatin" (6 trials), "Docetaxel" (6 trials) and "Abemaciclib" (5 trials). Other intervention names were less common.

The vast majority of trials in "Minnesota Oncology Hematology , P.A." are 58 trials for "All" genders, 17 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "Minnesota Oncology Hematology , P.A.". undefined are not yet recruiting, 10 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 51 completed trials in Minnesota Oncology Hematology , P.A., undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Minnesota Oncology Hematology , P.A., 6 "Phase 1" clinical trials were conducted, 45 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Minnesota Oncology Hematology , P.A. has several departments that took part in Clinical trials: "Minnesota Oncology - Burnsville" - 115 trials, "Minnesota Oncology Hematology PA-Maplewood" - 462 trials, "Minnesota Oncology Hematology PA-Woodbury" - 453 trials, "Minnesota Oncology Hematology" - 23 trials, "Minnesota Oncology Hematology, P.A." - 7 trials, "Minnesota Oncology-Minneapolis" - 9 trials, "US Oncology Research at Minnesota Oncology" - 2 trials